Huan Yuan Bio: The net loss in 2025 decreased by 10109.73 million yuan compared to the previous year.

Announcement from Huan Yuan Biotech: The company is projected to achieve revenue of 267.66 million yuan in 2025, an increase of 7.86% compared to the same period last year. The net profit attributable to the owners of the parent company is expected to be -220.72 million yuan, a decrease in losses of 101.09 million yuan compared to the previous year. The net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be -232.02 million yuan, a decrease in losses of 103.89 million yuan compared to the previous year. During the reporting period, the domestic biopharmaceutical industry faced both opportunities and challenges, showing a complex situation of diversified development and intense market competition. The company will continue to focus on its main business of cell and gene therapy CRO/CDMO, and actively expand its strategic layout in the field of regenerative medicine applications with the support of national and industry development policies.